From the start of 2016, the RCVS will no longer allow veterinary surgeons or veterinary nurses to enter undocumented continuing professional development (CPD) on their records.
Under the RCVS Codes of Professional Conduct, veterinary surgeons are required to record a minimum of 105 hours of CPD over a three-year period, while veterinary nurses are expected to carry out 45 hours of CPD over the same period.
Historically, vets and nurses have been able to record 10 and 5 hours as undocumented private study per annum respectively. The RCVS Education Committee decided to discontinue the allowance for vets in May and the Veterinary Nursing Committee followed suit in June.
Julie Dugmore, RCVS Head of Veterinary Nursing, said: “As with the veterinary surgeons, this decision was made because it was felt that all CPD, including private study, should be properly documented on the CPD records of veterinary nurses.
“This change, however, is not intended to discourage private study which we recognise extends across a range of different types of learning, including reading, and can be very valuable for personal development, but merely that it should be properly documented.”
The College says it hopes the changes will also clear up uncertainty around the respective allowances for veterinary surgeons and veterinary nurses, as some were under the impression that private study, even if it was documented, could only be classed within that category.
The Education Department is also in the process of reviewing the information available to veterinary surgeons and veterinary nurses regarding what counts as CPD, in order to clear up uncertainty and provide more specific examples for each learning category.
Information about CPD for veterinary surgeons can be found at www.rcvs.org.uk/cpd, while for veterinary nurses the information is available at www.rcvs.org.uk/vncpd
Discospondylitis describes the infection of an intervertebral disc and its adjacent cartilaginous end plates and vertebral bodies.
It is commonly bacterial or fungal in origin.
The disease can be challenging to diagnose as signs are variable and sometimes vague.
For the research, neurology specialists retrospectively examined cases which presented at multiple referral sites that have furthered the understanding, clinical and imaging features of discospondylitis.
To date MRI has been the imaging modality of choice, with consistent CT imaging features of discospondylitis in dogs and cats not previously reported in detail.
However with the increased availability of CT in clinical practice, the research set out to examine CT features that could support a diagnosis of discospondylitis.
Discospondylitis in cats is uncommon, and very little research had been undertaken in this area. This research group therefore reported clinical presentation and imaging data about a population of cats, to support the future diagnosis of these cases.
During the three studies*, the researchers found that:
The studies
Dr. Lauren Finka, a researcher at the University of Lincoln, has developed L-CAT, a new tool for assessing behaviour in cats at rehoming centres and help match them to the ideal new home.
During the course of her PhD studies, which were part funded by COAPE (Centre of Applied Pet Ethology), Lauren discovered inconsistencies in the current models and perceptions of behaviour traits used in re-homing cats.
For example, one of the most common behaviours associated with affection towards humans is the activity of rubbing. Initial results suggested that this is often very inconsistent, as are several other behaviours that were previously thought to to be important in assessing a cat's underlying temperament. Dr Finka’s studies showed that it all depends much more on the specifics of the physical and social context of interactions and that these may change on a daily basis. It was found that on one day a cat might rub against a person ten times, but the next day rub against the same person only once.
The Lincoln Cat Assessment Tool (L-CAT) was developed during this research. COAPE says it is the first of its kind to offer a suitably robust, reliable and easy-to-use way of assessing behaviour in cats at re-homing centres, as well in predicting new owner satisfaction based on those assessments.
The organisation goes on to say that the potential welfare implications of this research are substantial, enabling cats to be properly but rapidly assessed, optimally managed, and suitably matched with would-be owners and thus shortening the length of time cats might spend in the re-homing centre.
L-CAT was tested to establish the possibility of predicting the future behaviour of cats after they had been adopted, as well as gauging how satisfied owners were likely to be with their cats. COAPE says the results generally confirmed that these outcomes were indeed possible, meaning re-homing staff could also use L-CAT to help manage the expectations of owners and potentially improve their satisfaction.
For more information, visit: www.coape.org
Zoetis has announced that the European Commission has granted marketing authorization for Simparica™ (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age.
Dr. Balázs Capári, a Hungarian veterinary specialist in small animal medicine who participated in clinical trials of Simparica said: "The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs. In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica is very palatable; the chewable tablet was easily taken by their dogs. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."
Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "At Zoetis, we focus our innovation on the most pressing needs of veterinarians, and that is what guided us to develop a new oral choice to provide dogs with persistent protection from fleas and ticks and treatment of mites that cause sarcoptic mange. Simparica is a result of the collaboration of Zoetis scientists worldwide, who share a determination to develop new medicines that deliver real value to our veterinary customers and the animals in their care. We are excited to bring this innovative medicine, Simparica, to veterinarians and dog owners across Europe."
The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, developed by Zoetis.
Zoetis says the marketing authorization for Simparica was based on the results of field studies conducted in seven countries, involving more than 800 dogs of various breeds from at least eight weeks of age and 1.3 kg of weight. Simparica was shown to provide efficacy for at least five weeks against ticks and fleas. It demonstrated a rapid onset of action, killing fleas before they have a chance to lay eggs and can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis. It proved effective in treating sarcoptic mange, a highly contagious skin disease in dogs.
In studies, Simparica killed all four species of tick dominant in Europe (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus) and species of flea that most frequently infect dogs in European countries (Ctenocephalides felis and Ctenocephalides canis). Simparica was well tolerated with no adverse events reported at the therapeutic dose.
Zoetis expects to launch Simparica in the EU in the first quarter of 2016. Simparica chewable tablets will be available in 5mg, 10mg, 20mg, 40mg and 80mg dosage strengths.
For more information about Simparica and full prescribing information, visit http://www.zoetis.com/products-services/companion-animals/dogs.
The course is aimed at veterinary professionals across Europe who want to advance their knowledge and diagnostic skills, progress their academic qualifications and gain recognition in their field.
The GPAdvCert in Small Animal Medicine is for veterinary surgeons who have already completed a General Practitioner Certificate in Small Animal Medicine (GPCertSAM) or a Postgraduate Certificate (PgC) in Small Animal Medicine.
Accredited by the European School of Veterinary Postgraduate Studies (ESVPS) and validated by Harper Adams University, the programme will be delivered in three, five-day blocks of training by globally recognised experts in three European training centres - Sheffield, UK; Porto, Portugal and Berlin, Germany. The programme includes a practical session in which delegates will perform an upper and lower gastrointestinal endoscopy under the guidance of their tutor.
David Babington MRCVS, Business Development Director of Improve International (pictured right), said: "Delegates attending our first GPAdvCert in Small Animal Medicine will enhance their skills and confidence in dealing with complex animal medicine cases. Each module will take their knowledge beyond Postgraduate Certificate level with more in-depth and advanced content covering topics as diverse as mycobacterial and ureteric disease. They will also learn how to design a detailed diagnostic plan and build an understanding of nuances in interpreting laboratory findings to enable them to manage cases requiring complex therapeutic management with confidence."
He added: "The qualification is a natural ‘next-step’ for veterinary surgeons wanting to further progress their knowledge of small animal internal medicine. It will help them to reduce the number of patients which are referred, retaining a higher level of income for their practice and will also provide them with skills which they can pass onto their team."
Improve says the successful achievement of the GPAdvCert will enable delegates to progress from a Postgraduate Certificate in Small Animal Medicine (or equivalent) to the Postgraduate Diploma in Advanced Veterinary Practice Sciences in the UK, which is awarded by Harper Adams University. This can, in turn, be used towards the award of a Masters Degree (MSc) in Advanced Veterinary Practice Sciences.
Muriel joined Pennard Vets as an office junior on 7th January 1950, when she was 15 years old
She earned a weekly wage of £1 10 shillings, equivalent to £1.50 in today’s money.
Andy Green, a Director at Pennard Vets, said: “Few people in this country have achieved what Muriel has.
"Pennard Vets has been around for over 125 years and Muriel’s journey with us has encompassed a staggering 70 years of that, making her one of only a handful of people in the UK who have completed 70 years with a single employer.
“Muriel is ever-present, reliable, caring, dependable and she makes the best biscuits around.
"She started work at our Sevenoaks practice as a 16-year-old in 1950, when it was just as likely a client would be bringing in a sheep, goat or horse as a dog or cat, and we used loose boxes outside for examinations, treatments isolation and even post-mortems.
“During the subsequent 70 years she was part of the growth in the practice from a single site to multiple sites.
"She was also fantastic at embracing the latest technology as the practice went from handwritten ledgers, double entry bookkeeping and dealing with the terribly difficult to decipher handwritten notes of the vets, to digitalisation, computers, online systems, email, mobile phones and a host of other technological advances.
“Throughout the years her role changed dramatically, and she learned new skills, adapted, and moved with the times, demonstrating our core values of continuous improvement, client focus, compassion and clarity every step of the way.
“When Muriel retired in 2020, sadly lockdown rules denied us the chance for a proper celebration, so we are very pleased to have been able to celebrate together with such a fabulous party.”
Muriel said: “When I started at Pennard Vets, the practice cared for large animals including horses, sheep and cattle on the local farms, but we also had some more unusual clients.
"A special highlight was fielding telephone calls from former Prime Minister, Sir Winston Churchill, who lived at Chartwell country house, near Westerham, in Kent and employed the practice to look after the health of the black swans living on the estate’s lake.
“Two of the biggest changes I saw during my seven decades at the practice were the business giving up farm work to focus on small animal work as dogs and cats became a bigger part of our families, and the transition from my handwritten notes in ledgers to modern computer systems, but I have always embraced change and enjoyed learning new skills.
"I miss everyone at Pennard Vets but will keep in touch and keep baking for them!”
A Lincolnshire couple desperate to find an alternative to Elizabethan veterinary collars, after their dog Tess suffered a traumatic experience, have invented a new range of wound coverings called Cozi-fit.
According to Terri and Dave Ward from Skellingthorpe near Lincoln, who designed the new product, Cozi-fit is the clear alternative to Elizabethan or Buster collars. It comes in five different sizes, and the couple say that Cozi-fit is already going down well with vets and pet owners alike.
The idea for the Cozi-fit came about after the Ward's dog Tess had a hysterectomy. Dave said: "The hysterectomy was stressful enough, but Tess then had to wear a collar to stop her licking the wound. We also had to isolate her from our other dogs and she quickly became depressed and stopped eating.
"We were so worried about her that I decided to try and make a replacement using a pillowcase which we attached to her collar and fastened round her torso and hindquarters. As the wound was covered she could be around our other dogs and her movement wasn't restricted in any way.
"I was so delighted with the result that I decided to refine my design and took it to our local vet to get his opinion and it kind of grew from there. The wound coverings now come in five different sizes to suit all dogs and cats and are made from durable cotton fabric.
"We now supply over 30 veterinary surgeries including a number of Companion Care vet surgeries as well as the RSPCA and are currently in negotiation with retailers up and down the country."
Peter Munro from Whitegates Veterinary Practice said he was impressed when Terri first came to him with her initial idea: "Cozi-fit wound covers have proved to be a great benefit in protecting abdominal and castration wounds from self-trauma, especially where collars are not well tolerated and we've had some really positive feedback from our clients."
Although the product has been well received since coming on the market Dave says there are still thousands of vets, breeders and pet owners who are unaware of Cozi-fit.
"Vets perform over three million operations every year in the UK, many of which will be neuters, caesarean sections or other types of abdominal surgery, and Cozi-fit is ideal for these types of procedures.
"It is easy to fit, allows free and natural movement at all times and is a more pleasant experience for both the animal and their owner."
For more information about Cozi-fit please visit http://www.cozi-fit.com/.
The study, which was led by Robert Hyde MRCVS from the School of Veterinary Medicine and Science at the University of Nottingham, aims to create an automated diagnostic support tool for the diagnosis of herd level mastitis origin, an essential first step of the AHDB mastitis control plan.
Mastitis data from 1,000 herds’ was inputted for several three-month periods. Machine learning algorithms were used to classify herd mastitis origin and compared with expert diagnosis by a specialist vet.
The machine learning algorithms were able to achieve a classification accuracy of 98% for environmental vs contagious mastitis, and 78% accuracy was achieved for the classification of lactation vs dry period environmental mastitis when compared with expert veterinary diagnosis.
Robert said: “Mastitis is a huge problem for dairy farmers, both economically and in welfare terms. In our study we have shown that machine learning algorithms can accurately diagnose the origin of this condition on dairy farms. A diagnostic tool of this kind has great potential in the industry to tackle this condition and to assist veterinary clinicians in making a rapid diagnosis of mastitis origin at herd level in order to promptly implement control measures for an extremely damaging disease in terms of animal health, productivity, welfare and antimicrobial use."
Reference
The survey of 1,019 dog owners was conducted by petbuzz in December 2022.
Veterinary cardiology specialist, Dr Rachel James, said: “The CKCS has long been a very popular breed of dog in high demand, due to their loving and placid nature making them perfect family pet.
"We know that sadly at least 50% of CKCS have evidence of MVD disease by the time they are five, with 98% of dogs affected in their lifetimes.
"However, we can help our clients when selecting this breed to choose a puppy that is less likely to develop MVD at an early age, by utilising the heart testing scheme (Doppler heart testing).
"Prospective owners should be asking to see test results for the parents, grandparents, and even better great grandparents too, on both maternal and paternal sides.
"In addition breeders need more support and education to encourage the use of the heart testing scheme and how this can enable them to choose the best dogs to breed from.
"Furthermore we should be encouraging breeders to breed from dogs only when they are at least 3 years of age.”
Vita Animal Health commissioned the survey to raise awareness of the condition and to remind owners to use their vet’s expertise.
Vita’s veterinary nurse, Tara Evans, said: “The CKCS is a very popular breed of dog, perhaps set to be more so now King Charles III is reigning monarch.
"This survey has shown that awareness of mitral valve disease – which is very common in this breed – is not as good as it could be.
"We want to support vets in raising awareness and have useful resources such as our heart disease infographic (www.vitaanimalhealth.com/common-signs-of-heart-disease) that we welcome all vets in using.”
Hill's Pet Nutrition has highlighted recent studies which, the company says, prove that feeding a food enriched with omega-3 fatty acids from fish oils to dogs with osteoarthritis results in a reduction in NSAID dosage of up to 25%1, owner observed improvements in clinical signs3, and improved weight bearing ability2, 7
The claim that food can effectively support medical treatment follows in the wake of two published and one in press study in the Journal of the American Veterinary Medicine Association (JAVMA). These demonstrate that omega-3 enriched food (in this case Hill's Prescription Diet j/d Canine) has significant effects on weight bearing and helps reduce NSAID dosage by up to 25 per cent, when fed to dogs with osteoarthritis 1, 2,3.
According to Hill's, the research demonstrates that in dogs the high levels of eicosapentaenoic acid (EPA) from fish oils can down-regulate the cartilage degrading enzyme aggrecanase1. In vitro studies have also identified that EPA resulted in a reduction in the amount of degraded cartilage residue produced4. High levels of omega-3 fatty acids can also help to reduce inflammation5,6.
The two studies that were recently published confirm that feeding a diet rich in omega-3 fatty acids aids in the management of osteoarthritis in dogs2,3. The randomized double-blinded controlled trials were carried out over three and six months respectively and involved a total of 165 dogs identified as suffering from mild to moderate osteoarthritis. After collating the results from almost 25,000 trial days, researchers were able to confirm a significant 'clinical improvement' from feeding a food fortified with fatty acids.
In the first study described in JAVMA, researchers found evidence that omega-3 fatty acids from fish oils resulted in improvements in weight bearing2. Objective measurement using force plate gait analysis demonstrated that dogs fed a test food fortified with fatty acids were seven times as likely to show improved weight bearing compared with dogs fed a control food.
In the second study, through a detailed questionnaire, owners also observed significant improvements in their dog's osteoarthritic condition3. Improvements observed covered the following signs: difficulty in rising from rest, limping, stiffness, soreness when touched, yelping or whimpering in pain, aggression, lagging on walks, reluctance to play and overall activity level.
Adrian Pratt, Veterinary Affairs Manager for Hill's Pet Nutrition, manufacturer of Prescription Diet j/d, which is enriched with omega-3 fatty acids, hailed the results as a breakthrough in the field of nutrigenomics (the study of the effects of nutrition on gene expression): "This research points the way to a new model for the management of osteoarthritis, using a clinically proven food to interrupt the cycle of damage and cartilage degradation, alongside graded levels of NSAIDs and proactive programmes to manage weight and adjust exercise routines. Clinicians now have the conclusive proof they need to recommend feeding omega-3 enriched food to ameliorate the signs of osteoarthritis in clients' pets and to adjust NSAID doses accordingly."
For further information on Hill's Prescription Diet j/d, please contact your Hill's Territory Manager or call 0800 282438.
References1. A multicenter study of the effect of a therapeutic food supplemented with fish oil omega-3 fatty acids on the Carpofen dosage in dogs with osteoarthritis. Fritsch A, Allen T, Dodd C, JAVMA in press2. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs. Roush J, Cross A, Renberg W, Dodd C, Sixby K, Fritsch A, Allen T, Jewell, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp67-733. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. Roush J, Dodd C, Fritsch A, Allen T, Jewell D, Schoenherr W, Richardson D, Leventhal P, Hahn K, JAVMA Vol 236 No 1, Jan 2010 pp 59-664. Eicosapentaenoate supplementation abrogates canine articular cartilage degeneration in in vitro explant culture systems, Caterson B, Cramp J, Little C B et al, Hills European Symposium on osteoarthritis and joint health 2005 14-195. Dietary modification of inflammation with lipids, P C Calder, Proceedings of the Nutrition Society 2002 345-3586. Dietary polyunsaturated fatty acids and inflammatory mediator production, James M J, Cleland L G, Gibson R A, Am J Clin Nut 2000: 71 suppl 343S- 358S7. Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995; 206 (6): 807-811.
Defra has announced plans to form a new Animal Health and Welfare Board for England which will bring experts including farmers, veterinary surgeons, welfare experts and others from outside Government together with the Chief Veterinary Officer and civil servants to make direct policy recommendations on policy affecting the health and welfare of all kept animals such as farm animals, horses and pets.
According to Agriculture Minister Jim Paice, it is the first time that people affected by Government policy on animal health and welfare will make recommendations on those policies directly to Ministers.
Mr Paice said: "This is a completely new way of working. It replaces the old ways, where the people most affected by decisions were kept at arm's length from policy making on those subjects.
"This is about the Big Society not just existing in our communities, but in the heart of Government - helping to put the decisions in the hands of those who are doing the work on the ground.
"We've already seen the success of a partnership between farmers and the Government with the work that's been done on bluetongue - which has seen the disease virtually eradicated in this country."
Final decisions on animal health and welfare policy will remain in the hands of Government Ministers.
The Board will be made up of around 12 members, 5 senior Defra officials including the Chief Veterinary Officer, and 7-8 external members including the chair. The external members will have experience and knowledge of kept and farmed animals, animal and veterinary science, and animal welfare, and could be farmers, veterinarians, animal welfare experts.
The Board and its members will have to represent the views of all stakeholders so will be expected to communicate with them regularly.
The Board's responsibilities will include:
The Board will not be set up as a non departmental public body or arms length body. It will form part of the internal structure of Defra.
Commenting on the announcement, Harvey Locke, President of the British Veterinary Association, said: "The BVA is delighted that both the Advisory Group and Ministers have taken note of the veterinary profession's views in drawing up these plans.
"We said from the outset that genuine responsibility sharing has to be achieved before cost sharing can be discussed and we warned against earlier plans to separate animal health policy from animal welfare policy, as the two are intrinsically linked.
"Animal health and welfare policy issues require expert, scientific input and it will be essential that the new Board includes veterinary representation. We believe that the Board will provide the right mechanism for ensuring decisions are based on sound science.
"The new Board will also have to work closely with the three devolved administrations to ensure that animal health and welfare policies across the UK are joined up and complementary."
Bob was a member of RCVS Council from 1992 until 2004 and was President in 1999/2000. During his time on Council he also served as a member of all of the major committees of that time, with the exception of the Disciplinary Committee, and chaired several of the subject boards for the RCVS Diplomas.
Current RCVS President Chris Tufnell said: "Bob was 100% responsible for my involvement with the RCVS, putting me forward for a working party in my first year in practice. Throughout his career he nurtured young professionals who he genuinely saw as the future and he was particularly dedicated to furthering and improving the education and development of veterinary surgeons, as demonstrated by his involvement in the RCVS Diplomas, the College’s continuing professional development (CPD) board and the former RCVS Trust.
"His dedication to our profession was exceptional and his kind and erudite observations, both public and private, were always welcome. We will miss him and our thoughts are with his family at this difficult time."
Photo courtesy Dulwich College.
VetSurgeon.org is once again playing host to the RCVS Elections Section, where veterinary surgeons can now come and question the candidates lining up to regulate them.
This year, there are 10 candidates fighting to win one of 6 places on council. You can 'meet the candidates' here, read their manifestos, and then ask them questions either privately - via the 'Start Conversation' link in their profile - or publicly in the RCVS Forum.
There is a new incentive to vote this year: the RCVS will donate 20p to the Disasters Emergency Committee (DEC) Haiti Earthquake Appeal on behalf of every voter that takes part.
The RCVS has also made it easier to vote, with the addition of SMS text voting to the online and postal options.
However, I hope more than anything else that the opportunity to challenge the candidates and find out what makes them tick in the RCVS Elections Forum will be fun and really help inspire you, the electorate, to get involved.
The research is being carried out by XLChief Operating Officer Kerrie Hedley, building on work she carried out last year which she talks about in a podcast currently hosted on the Veterinary Women website.
Female vets who would like to take part in the research, whether or not they are business owners, are invited to email Kerrie at kerrie.hedley@xlvets.co.uk.
Kerrie says she wants to ensure she hears a wide variety of viewpoints: “If women are averse to leadership or doubtful about the benefits of leadership, they should be heard too. There’s a great deal of support and momentum behind this project within the XLVets community and it’s something we all think is hugely important for the future of the profession. We had a tremendous response to our last call for participants and I’m looking forward to gaining more insight into this important topic and helping to develop innovative solutions.”
The researchers say the effectiveness of cheaper devices could result in wider use amongst farmers, vets and hoof trimmers helping to identify lameness earlier.
The study, led by RVC undergraduate veterinary student, Aidan Coe, alongside Dr Nicola Blackie, a senior lecturer in Production Animal Science at the RVC, compared the thermal images of 83 cows’ hind feet, captured with both high and low cost thermal imaging devices.
Very little difference was identified in the performance and quality of the devices despite the low-cost device being 2% the cost of the high cost device.
Images captured suggested that low-cost thermal imaging devices would be the most cost-effective choice to aid in the identification of lameness.
This study highlights the effectiveness of cheaper infrared thermal imaging devices in identifying the condition which has the potential to lead to the wider use of the devices by farmers, vets and hoof trimmers, in turn allowing the condition to be identified earlier.
Whilst high-cost devices have sometimes been used to detect lameness in cattle, the price point of up to £20,000 and fragility has previously limited their usefulness in a farm setting.
Aidan Coe, Undergraduate Veterinary Student at the RVC, and lead researcher on this paper, said: “There is a possibility that low-cost infrared thermal imaging devices could be used as an objective, cost-effective method of assessing the lameness of the national herd, which may prove a useful adjunct to the current lameness detection methods.”
The full paper can be accessed at: https://www.mdpi.com/2306-7381/9/8/414
Zoetis says the new product is designed to stimulate both cell-mediated and antibody-based immunity, providing a broad immune response that mimics a natural infection.
The company says CircoMax Myco has demonstrated robust performance in field conditions, delivering improvements in average daily gain (ADG) and close-out weights versus negative controls, helping producers get more kilograms of pork to market.
CircoMax Myco comes in a ready to use single-dose combination with a duration of immunity (DOI) of 23 weeks against both PCV2 and M. hyopneumoniae.
Alvaro Aldaz, Director, Global Commercial Development, Swine, Zoetis, said: “The swine industry needs to adapt to evolving challenges and our research has consistently demonstrated that with its unique technology CircoMax Myco offers robust protection against PCV2 and M. hyopneumoniae.
"It also shows that this new product offers the best chance at protection against continuously evolving PCV2 genotypes – providing a broader umbrella for pig health and productivity.
"Analysis of new European PCV2 strains isolated in multiple countries confirm that CircoMax Myco offers broader coverage than competitor vaccines based on PCV2a only.”
Virbac has announced a special promotion in which practices can earn a specialist ear instrument kit worth £100
The kit, which has been designed by Virbac vets in consultation with a number of veterinary dermatologists, is available with multiple purchases of the otitis treatment EasOtic, and the neutral pH glycotechnology ear cleaner Epi-Otic.
Product manager Chris Geddes MRCVS said: "Each kit contains a haemostat, ear forceps, 3 various cerumen scoops and a Spreulls ear-flushing needle. Basically it's the best ear equipment for daily use by practitioners. For a limited period we are giving away one set FOC with every purchase of 25 bottles of EasOtic and 25 bottles of Epi-Otic."
Chris added: "When it comes to treatment of otitis, we know that client compliance is a key issue. The award-winning design of EasOtic makes it an extremely easy product to use. The 'one pump' delivery system helps deliver more accurate dosing and minimises animal stress during application. This means that treatment courses are more likely to be completed, thus optimising results and client satisfaction all round."
For further information, please contact your local Virbac territory manager or call Virbac on 01359 243243.
An amendment to the EU's draft budget for a €2 million pilot research project into homeopathy and phytotherapy for farm animals has been approved today by the European Parliament's Agriculture Committee.
BVA President Harvey Locke, said: "Millions of Euros have already been spent on trying to prove the scientific efficacy of homeopathic medicines. To date we have not seen any data to prove they can be effective in the treatment of bacterial infections.
"Whilst it is unlikely that €2 million will be able to determine whether or not there is a basis for claiming homeopathic products can work, we welcome European investment in veterinary research and hope that the results of the pilot will be useful."
A new survey by Petplan has given an insight into how veterinary nurses regard their job.
The survey, conducted at BVNA Congress, found that 73% of nurses feel that clients do not have a sufficient understanding of their role in practice.
Louisa Baker, the 2008 Petplan Vet Nurse of the Year, said: "Clients are often not aware of the skills required to be a vet nurse. Most clients believe we just handle the animals whereas we are often involved with surgical activities such as stitching and preparing drips."
Arguably, if pet owners under-appreciate the role of the nurse in practice, then they might also be expected to place a lower financial value on the care they provide. If that is the case, then it makes a lot of sense for vets and practice owners to find novel ways of communicating the breadth of work that nurses do, and its importance, to clients.
Other findings included 40% of nurses agreeing that direct contact with animals, such as caring for them through recovery, is the best part of the job. 54% told Petplan that they find the job extremely rewarding.
Nearly all nurses (99%) said that they value training and CPD to further their careers.
To support this desire to learn, Petplan has launched its Petplan Insurance Advisor training scheme. Already, over 500 nurses have completed one of the scheme's CPD qualifying modules.
The scheme enables the development of individual skills such as the ability to sell products and gain confidence with clients. Available online, vet nurses can participate in the scheme at work or at home. Visit http://www.petplanpia.co.uk/ for more information.
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
The partnership includes a minimum donation of £10,000 which the company hopes to bolster with additional volunteering and fundraising support.
Gerard Ensink, Head of Animal Health UK and Ireland at Boehringer Ingelheim said: “We are truly delighted to be supporting StreetVet.
“There is already so much passion for the charity within our company.
"Even before we announced this charity partnership, several of our colleagues have been volunteers with StreetVet in a personal capacity.
"We look forward to supporting StreetVet and believe that together we can make a real difference to individuals and their pets who are experiencing homelessness.”
https://www.streetvet.co.uk
Axiom Laboratories has launched MiPetAllergy, a pet allergy test which the company says is not affected by medication and which requires no withdrawal period prior to testing.
Axiom developed the MiPetAllergy in partnership with ALK, which makes Artuvetrin. With its food elimination diet selector tool, developed in association with Royal Canin, it tests against as many as 80 environmental allergens and foods.
Dan Sherry, General Manager at Axiom, said: "Allergies are increasing among companion animals and identifying accurately which allergen is causing the problem in a particular pet can be one of the toughest challenges veterinary staff face in practice.
"MiPetAllergy represents two and half years of research so we are delighted to announce its arrival. Axiom is confident that there will be complete concordance between the screen and panel results that they are offering a money back guarantee if they are discordant. We hope it will help practices dealing with allergy patients to identify and treat for the specific allergens causing their symptoms."
Martyn Carpenter, Director of Axiom, added: "The introduction of the MiPetAllergy testing is timely as it coincides with the change in Axiom’s supplier of immunotherapy. During November and December 2014 the Veterinary Medicines Directorate (VMD) started rejecting applications for STC’s and advising that European Licensed immunotherapy products should now be used in the UK as part of the Cascade. Both our new allergy test and new vaccines are manufactured by the same company."
The upgraded site uses 'machine learning', a type of artificial intelligence based on pattern recognition, to offer personalised content. The technology is now commonly used in consumer sites, such as Netflix and Amazon, but until now has not been used in the veterinary world. Content is further personalised for those vets and nurses that complete their profile on the site.
The upgrade was commissioned after Boehringer carried out a user experience survey of its old website, which revealed that whilst vets appreciated the CPD and educational materials, many were trawling through content that was not of interest to them or struggling to find what they wanted.
Jemima Mead, brand manager at Boehringer, said: "We aimed to create an engaging portal – a one-stop shop for vets who want to access high quality CPD and/or relevant information about any of our products. Vets are busy people so need to find relevant information quickly – giving them more time to focus on their clinical responsibilities. Our new slick site, tailored to their individual professional preferences, provides a valuable service that simply has not existed before."
The association says that the day of lectures is mainly targeted at those who are starting on their path of ophthalmology, but old hands may also learn a few new tricks.
Topics will include how to get the most from the ophthalmic examination, diagnostics and what options there are for career growth in our specialty.
There will be live panel discussions to give attendees the opportunity to ask any questions they have.
Tickets costs £100+VAT for BrAVO members, £60+VAT for nurses and interns, and £40+VAT for students.
The deadline for registration is Tuesday 16th March at 5:00pm.
To book your ticket, visit: https://www.eventbee.com/v/bravo-spring-meeting-2021/event?eid=164693974#/tickets
NOAH Chair Gaynor Hillier said: "The production and supply of veterinary medicines is totally dependent on complex international supply chains that must continue to function effectively after Brexit, their unique status being recognised in the recent government White Paper.
"Raw materials will need to arrive at manufacturing sites and veterinary medicines will need to be transported across borders to meet market requirements. Any border delays, additional complex processes or increased costs will risk medicines availability for UK vets, farmers and all our animals."
According to a recent NOAH member survey, less than 15% of companies say they are prepared for a 'hard Brexit' with the vast majority of respondents saying they are not fully prepared should there be a reversion to WTO rules on 30 March 2019.
NOAH says this is not through lack of effort or unawareness of the need to act, but due to the magnitude of the complex tasks involved in such a specialist sector, coupled with uncertainty over what a 'no-deal' Brexit will look like.
In contrast, almost 60% of companies said they are prepared for a transition period to December 2020. Even then, NOAH says the proposed transition period will not be enough in some cases.
The survey examined product availability in the UK: almost 55% of respondents reported potential availability issues for the UK market impacting more than 40% of their products. The full spectrum of types of products (from vaccines to painkillers: from antibiotics to wormers) across all animal species (farm, equine and pet) are potentially at risk, with particular concerns raised around the supply chain for vaccines.